| payload |
{"created_at":"2026-04-11T03:10:51.104 {"created_at":"2026-04-11T03:10:51.104915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:5f1a2e291704cfb5","evidence_event_ids":["evt_f805dc39f6b0"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1802768/0001140361-26-014241.txt","as_of":"2026-04-11T03:10:51.104915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1802768/0001140361-26-014241.txt","company":"Royalty Pharma plc","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1802768/0001140361-26-014241.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_2bce81754a191def","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1802768/0001140361-26-014241.txt","content_type":"text/plain","enriched_at":"2026-04-11T09:05:02.498030+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1802768/0001140361-26-014241.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1802768/0001140361-26-014241.txt","source_event_id":"evt_f805dc39f6b0","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEFA14A","fp":"4ab7cb032ee69ef7","kind":"sec_filing","published_at":"20260410","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-10"],"entities":[{"asset_class":"equity","name":"Royalty Pharma plc","relevance":"high","symbol":"RPRX","type":"issuer_company"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the supplied text (no prior filing comparison content included).","No substantive proxy content (e.g., proposals, board actions, voting matters) is included in the provided excerpt beyond the form header/cover information.","The signal type is labeled discovery_sec_filing_delta, but the delta details (what differs from the prior state) are not present in the provided text."],"key_facts":["Form type: DEFA14A.","Filer/issuer: Royalty Pharma plc.","SEC filing date shown as 2026-04-10 (accession number 0001140361-26-014241).","Document indicates it is a Schedule 14A proxy statement under Section 14(a) of the Securities Exchange Act of 1934.","The filing is marked as \u201cDefinitive Additional Materials.\u201d","Payment of filing fee: \u201cNo fee required.\u201d","The document header shows \u201cFiled as of date: 20260410\u201d and \u201cDate as of change: 20260410.\u201d"],"numeric_claims":[{"label":"SEC filing date (as of date)","value":"2026-04-10"},{"label":"SEC accession number","value":"0001140361-26-014241"},{"label":"Public document count","value":"4"}],"primary_claim":"Royalty Pharma plc filed Form DEFA14A with the SEC on 2026-04-10 as definitive additional materials for a Schedule 14A proxy statement.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Royalty Pharma plc filed a DEFA14A (definitive additional materials) with the SEC on 2026-04-10. The filing is a Schedule 14A proxy statement amendment/additional materials submission, with no filing fee required.","topics":["SEC filing","DEFA14A","Schedule 14A","proxy statement","definitive additional materials"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEFA14A \u00b7 Royalty Pharma plc \u00b7 Filed 20260410","ticker":"RPRX","tickers":["RPRX"],"title":"RPRX filed DEFA14A","url":"https://www.sec.gov/Archives/edgar/data/1802768/0001140361-26-014241.txt"}}... |